Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 3 of 24, showing 10 Applications out of 238 total, starting on record 21, ending on 30

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

21.

ECCT/25/07/04   PROPS Trial
    Efficacy of probiotic supplementation in preterm and small for gestational age infants. A multi-centre, placebo-controlled, individually-randomised trial   (Probiotics in preterm and small for gestational age infants, PROPS trial)   
Principal Investigator(s)
1. Mourine Ikol
Site(s) in Kenya
1. Kisii Teaching and Referral Hospital (Kisii county)
2. Homabay County Referral Hospital (Homa Bay county)
3. Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county)
4. Migori County Referral Hospital (Migori county)
 
20-04-2026 View

22.

ECCT/25/07/03   PROPS Trial
    Efficacy of probiotic supplementation in preterm and small for gestational age infants. A multi-centre, placebo-controlled, individually-randomised trial   
Principal Investigator(s)
1. Joyce Akuka
Site(s) in Kenya
1. Migori County Referral Hospital (Migori county)
2. Homabay County Referral Hospital (Homa Bay county)
3. Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county)
4. Kisii Teaching and Referral Hospital (Kisii county)
 
14-04-2026 View

23.

ECCT/25/07/02   PROPS Trial
    Efficacy of probiotic supplementation in preterm and small for gestational age infants. A multi-centre, placebo-controlled, individually-randomised trial   (Probiotics in preterm and small for gestational age infants, PROPS trial)   
Principal Investigator(s)
1. Meshack Liru
Site(s) in Kenya
1. Homabay County Referral Hospital (Homa Bay county)
2. Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county)
3. Kisii Teaching and Referral Hospital (Kisii county)
4. Migori County Referral Hospital (Migori county)
 
14-04-2026 View

24.

ECCT/25/06/02   Neosep1
    An open-label randomised controlled trial comparing novel combination and currently used antibiotic regimens for the empiric treatment of neonatal sepsis with a run-in confirmatory pharmacokinetic phase.   
Principal Investigator(s)
1. Nayirat Mohamed Dormohamed
Site(s) in Kenya
1. Coast General Teaching and Referral Hospital (Mombasa county)
 
02-10-2025 View

25.

ECCT/25/06/01   Neosep1
    An open-label randomised controlled trial comparing novel combination and currently used antibiotic regimens for the empiric treatment of neonatal sepsis with a run-in confirmatory pharmacokinetic phase.   
Principal Investigator(s)
1. Christine Nafula Manyasi
Site(s) in Kenya
1. Mbagathi County Referral Hospital (Nairobi City county)
 
02-10-2025 View

26.

ECCT/25/05/12   SAFIRE
    A multicentre open-label, non-inferiority adaptive platform randomised controlled trial to evaluate the efficacy, safety, and tolerability of antimalarials for the treatment of uncomplicated malaria in the first trimester of pregnancy   
Principal Investigator(s)
1. Hellen Barsosio
Site(s) in Kenya
The Kenya Medical Research Institute (KEMRI), Centre for Global Health Research (CGHR)
 
15-10-2025 View

27.

ECCT/25/05/11   Sparkle study site-1406
    A phase III, Multicenter, Randomized, Placebo Controlled, Double blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Frequent Vaso-Occlusive Crises   
Principal Investigator(s)
1. Doreen Mutua
Site(s) in Kenya
1. Victoria Biomedical Research Institute (Kisumu county)
2. Ahero Clinical trials Unit (Kisumu county)
3. International Cancer institute (Uasin Gishu county)
4. Kondele Childrens Hospital (Kisumu county)
5. KEMRI/CRDR KEMRI Clinical Research Annex (Siaya county)
6. Gertrudes Children’s Hospital (Nairobi City county)
 
03-02-2026 View

28.

ECCT/25/05/08   Floral roll over study
    An open-label, multi-centre, rollover study to characterise long-term safety and efficacy of etavopivat in adults, adolescents and children who have sickle cell disease or thalassaemia and have completed a treatment period in an etavopivat study.   
Principal Investigator(s)
1. Prof Videlis Nduba
Site(s) in Kenya
1. KEMRI Siaya Clinical Research Annex (Siaya county)
2. Center for Research in Therapeutic Sciences (CREATES) (Kisumu county)
3. Gertrudes Childrens Hospital (Nairobi City county)
4. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county)
5. KEMRI WALTER REED KERICHO (Kericho county)
6. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county)
7. KEMRI Kondele Children\'s Hospital (Kisumu county)
 
05-03-2026 View

29.

ECCT/25/05/07   Floral roll over study
    An open-label, multi-centre, rollover study to characterise long-term safety and efficacy of etavopivat in adults, adolescents and children who have sickle cell disease or thalassaemia and have completed a treatment period in an etavopivat study.   
Principal Investigator(s)
1. Prof Jessie Githanga
Site(s) in Kenya
1. Gertrudes Childrens Hospital (Nairobi City county)
2. KEMRI Kondele Children\'s Hospital (Kisumu county)
3. KEMRI Siaya Clinical Research Annex (Siaya county)
4. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county)
5. KEMRI WALTER REED KERICHO (Kericho county)
6. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county)
7. Center for Research in Therapeutic Sciences (CREATES) (Kisumu county)
 
21-11-2025 View

30.

ECCT/25/05/06   Hibiscus 2 - Site 254
    A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease.   
Principal Investigator(s)
1. Doreen Mutua
Site(s) in Kenya
1. Site 254 - Gertrude\'s Children\'s Hospital (Nairobi City county)
 
26-11-2025 View